

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2025

GlycoMimetics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-36177
(Commission File Number)

06-1686563
(IRS Employer
Identification No.)

P.O. Box 65
Monrovia, Maryland 21770
(Address of principal executive offices, including zip code)

(240) 243-1201
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---------------------------------|-------------------|-------------------------------------------|
| Common Stock, \$0.001 par value | GLYC | The Nasdaq Stock Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

As previously disclosed, GlycoMimetics, Inc., a Delaware corporation (“GlycoMimetics”), entered into an Agreement and Plan of Merger and Reorganization, dated October 28, 2024, which agreement was amended on February 14, 2025 and April 28, 2025 (as amended, the “Merger Agreement”), with Gemini Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of GlycoMimetics (“First Merger Sub”), Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of GlycoMimetics (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, First Merger Sub, will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the “First Merger”), and Crescent will merge with and into Second Merger Sub (the “Second Merger” and, together with the First Merger, the “Merger”), with Second Merger Sub being the surviving entity of the Second Merger. After the completion of the Merger, Second Merger Sub will change its corporate name to “Crescent Biopharma Operating Company, LLC” and GlycoMimetics will change its name to “Crescent Biopharma, Inc.” The Merger Agreement was unanimously approved by the board of directors of each of GlycoMimetics and Crescent.

In connection with the Merger, GlycoMimetics filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, which includes a proxy statement/prospectus (the “Form S-4”), most recently amended on May 12, 2025 and declared effective by the SEC on May 14, 2025. GlycoMimetics and Crescent commenced mailing of the definitive proxy statement/prospectus on May 14, 2025.

The following supplemental disclosures should be read in conjunction with the Form S-4, which should be read in its entirety as supplemented. The inclusion in this supplement to the Form S-4 of certain information should not be regarded as an indication that any of GlycoMimetics or its directors, affiliates, officers, or other representatives, or any other recipient of this information, considered, or now considers, it to be material, and such information should not be relied upon as such. Defined terms used but not defined herein have the meanings set forth in the Form S-4. For clarity, new text within restated paragraphs from the Form S-4 is highlighted with **bold, underlined text**, and deleted text within restated paragraphs from the Form S-4 is highlighted with ~~strikethrough text~~.

The disclosure under the heading “Background of the Merger” is hereby amended and supplemented by replacing the second and third paragraphs beginning on page 121 of the Form S-4 in their entirety with the following:

Following receipt of bid letters on August 21, 2024, Lucid reviewed the proposals and selected 11 potential counterparties that most strongly aligned with GlycoMimetics’ ~~stated requirements and projected closing cash levels~~ **regarding time to closing, ability to raise capital and the need for and amount of a concurrent financing, likelihood of closing and the amount of cash that GlycoMimetics would be required to have as of the closing date**. Lucid engaged in discussions with each of the 11 finalists to assess their interest in moving forward with a potential transaction and based on those conversations, identified that 5 of the 11 potential counterparties would be interested in presenting to GlycoMimetics’ management. Based on discussions with the management of GlycoMimetics regarding GlycoMimetics’ updated expense budgets and anticipated cash forecasts through the potential closing of a reverse merger transaction, Lucid reprioritized discussions with the potential counterparties to focus on 10 candidates believed to be most interested in and reasonably able to consummate a reverse merger with GlycoMimetics. After diligence calls with each of these 10 counterparties, three viable targets were identified and the ~~remaining other~~ **remaining other** seven potential counterparties were deprioritized ~~due to transactability issues, including cash needs, milestone timing, free float considerations, and valuation concerns~~ **for the reasons listed above, with a particular focus on the inability to raise the necessary funds for a concurrent financing**. GlycoMimetics’ management reviewed with Lucid the non-binding proposals provided by the three remaining potential counterparties and, during the week of September 2, 2024, met with representatives of each potential counterparty. Following the counterparty management presentations and after further diligence, Lucid worked with GlycoMimetics’ management to refine GlycoMimetics’ estimate of ~~closing its cash deliverable at a~~ **on** projected closing ~~and determined that two of the three potential counterparties would not be~~ **dates, and two parties remained** viable choices; **Crescent; and another potential counterparty, “Party A”**. With respect to **Party A** ~~the remaining potential counterparty (“Party A”)~~, on September 10, 2024, GlycoMimetics’ management directed Lucid to present Party A with a proposed term sheet for a reverse merger reflecting, among other items, the anticipated closing cash deliverable by GlycoMimetics and a reduced equity valuation for Party A. Thereafter, on September 12, 2024, Party A presented a further revised proposed term sheet with additional proposed revisions, including a readjusted Party A valuation.

~~Following the announcement of topline results~~ **Throughout this period**, GlycoMimetics' management continued to explore potential monetization transactions for GlycoMimetics' other programs, but was unable to identify any other viable transactions. On September 5, 2024, following extensive marketing efforts and discussion with multiple potentially interested parties, GlycoMimetics sold its rivipansel program to Biossil Inc. for approximately \$1 million in cash.

The disclosure under the heading “Background of the Merger” is hereby amended and supplemented by replacing the final paragraph beginning on page 122 and carrying over onto page 123 of the Form S-4 in its entirety with the following:

Following Crescent's presentation, the GlycoMimetics Board determined that Crescent was a counterparty that merited serious consideration because (i) it required a minimal amount of GlycoMimetics' cash and would therefore allow for sufficient time to complete the proposed transaction, (ii) the company was backed by a reputable investor with a history of successful reverse merger transactions, and (iii) the company was confident that it could secure strong interest with respect to an investment that would be contemplated to close concurrently with the closing of the proposed merger. As a result, the GlycoMimetics Board focused its efforts on pursuing a transaction with Crescent while continuing to discuss a potential transaction with Party A in case a transaction with Crescent did not come to fruition. The GlycoMimetics Board determined that it should pursue a transaction with Crescent in light of the GlycoMimetics Board's view that (i) the liquidation of GlycoMimetics was not reasonably likely to result in superior value to GlycoMimetics' stockholders when compared to the proposed transaction; (ii) the \$8 million enterprise value ascribed to GlycoMimetics would give GlycoMimetics' stockholders a significant opportunity to participate in the potential growth of the Combined Company following the merger at the negotiated exchange ratio; (iii) the preliminary due diligence performed to date and the recommendations of its advisors with respect to the viability of Crescent's assets, including the proposed concurrent \$125 million PIPE financing, would provide a meaningful opportunity to GlycoMimetics' stockholders; (iv) the likelihood of consummation of the proposed transaction would be high given Paragon licensees' recent record of successful reverse merger transactions and substantial capital resources; and (v) the proposal from Crescent was more favorable to GlycoMimetics than the potential value that might have resulted from further pursuing other strategic transactions available to GlycoMimetics, including with Party A, in light of the extensive outreach process undertaken to date. To assist with the potential transaction, the GlycoMimetics Board discussed the establishment of a special transaction committee for the purpose of reviewing, negotiating and making recommendations to the GlycoMimetics Board regarding subsequent changes to the Crescent Term Sheet (the "Term Sheet Committee"). The Term Sheet Committee was formed for convenience of the GlycoMimetics Board and not because of any conflicts-related concerns with Crescent or Paragon. The GlycoMimetics Board approved the formation of the Term Sheet Committee and appointed Mr. Junius and Mr. Pearson to serve on the Term Sheet Committee. The GlycoMimetics Board delegated to the Term Sheet Committee the full power and authority of the GlycoMimetics Board to, among other things, consider, evaluate, negotiate and make recommendations to the GlycoMimetics Board regarding the Crescent Term Sheet. It was also discussed and concluded that the Term Sheet Committee would update and seek input from the GlycoMimetics Board as appropriate; and members of the GlycoMimetics Board who were not also members of the Term Sheet Committee would have timely access to the Crescent Term Sheet and any subsequent changes thereto. **The members of the Term Sheet Committee received no additional compensation for this assignment and the Term Sheet Committee was formally dissolved on October 28, 2024, immediately after the Company executed the Merger Agreement with Crescent.**

The disclosure under the heading “*Background of the Merger*” is hereby amended and supplemented by replacing the first paragraph beginning on page 123 of the Form S-4 in its entirety with the following:

On September 19, 2024 and September 20, 2024, GlycoMimetics’ management and the legal representatives and financial advisors to each of GlycoMimetics and Crescent continued to perform due diligence on Crescent and the potential strategic opportunity and held multiple discussions regarding, among other things, the form of the proposed transaction and related timelines; Crescent’s proposed increase of the level of concurrent PIPE financing with no concomitant change to GlycoMimetics valuation; the proposed development plan for Crescent’s technology and the indication under development; the potential contribution of additional assets to Crescent, including GlycoMimetics’ existing pipeline; the substantive economic terms of a potential reverse merger transaction; and the relative valuations to be ascribed to each party. Following these discussions, a revised Crescent Term Sheet was circulated to the Term Sheet Committee for approval, which was granted. Thereafter, on the evening of September 20, 2024, Lucid delivered a revised draft of the Crescent Term Sheet to Wedbush, proposing a reverse merger transaction ascribing an \$8,000,000 enterprise valuation to GlycoMimetics, a \$50,000,000 enterprise valuation of Crescent, a concurrent PIPE financing in the amount of \$125,000,000, and setting forth certain other material terms including (1) conditions to execution of any definitive agreement, (2) conditions to the closing of the business combination transaction; and (3) the exclusivity period.

During a diligence update call held on September 12, 2024, Crescent informed GlycoMimetics and representatives of Lucid that Crescent did not plan to retain, employ or otherwise engage any GlycoMimetics executives after the closing of the proposed merger. During a follow-up call on October 16, 2024, Crescent reaffirmed that position and further confirmed that the transaction structure contemplated no equity roll-over, retention equity or other employment-linked consideration for GlycoMimetics’ management team.

The disclosure under the heading “*Background of the Merger*” is hereby amended and supplemented by replacing the second to last paragraph beginning on page 123 of the Form S-4 in its entirety with the following:

On September 24, 2024, GlycoMimetics made the decision not to pursue a transaction with Party A. Party A is owned by a Chinese parent and GlycoMimetics was concerned about the unknown time it would take for Chinese regulatory bodies to clear the transaction. **The GlycoMimetics Board also confirmed at this meeting—after consultation with management and Lucid—that, given the going-concern uncertainties described in Note 1 to GlycoMimetics’ audited financial statements, it was not feasible to prepare financial projections and they would not be meaningful for use in evaluating the proposed merger or any alternative transaction. Additionally, no financial projections prepared by or on behalf of Crescent were provided to GlycoMimetics or Lucid at any time.**

The disclosure under the heading “*Background of the Merger*” is hereby amended and supplemented by replacing the second paragraph beginning on page 124 of the Form S-4 in its entirety with the following:

Between July 2023 and September 2024, GlycoMimetics entered into 14 confidentiality agreements with prospective counterparties, including biotechnology companies, discovery platforms and life-science investors, one of which was Paragon. 12 of these confidentiality agreements, including the one with Paragon, contained standstill provisions restricting the counterparty from acquiring GlycoMimetics securities or pursuing a control transaction which included “don’t-ask, don’t-waive” language that prohibited the counterparty from requesting a waiver of the standstill. These provisions automatically terminated in accordance with their terms upon the signing of the Merger Agreement. On October 16, 2024, GlycoMimetics executed an indemnity letter with Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated as placement agents in respect of the sale of securities underlying the proposed \$125 million concurrent PIPE financing.

The disclosure under the heading “*Selected Precedent IPO Companies*” is hereby amended and supplemented by replacing the table on page 137 of the Form S-4 in its entirety with the following:

| First-Trade Date | Issuer | Stage at IPO | Pre-Money Value (\$m) | Cash (\$m) | Debt (\$m) | Enterprise Value at IPO (\$m) |
|------------------|-----------------------|---------------------|-----------------------|--------------|-------------|-------------------------------|
| 9/13/2024 | Bicara Therapeutics | <u>Phase I</u> | <u>616.7</u> | <u>203.9</u> | <u>0.0</u> | 412.8 |
| 2/09/2024 | Adagene | <u>Phase I</u> | <u>853.3</u> | <u>75.2</u> | <u>8.0</u> | 786.1 |
| 7/21/2023 | Turnstone Biologics | <u>Phase I</u> | <u>186.3</u> | <u>49.2</u> | <u>0.0</u> | 137.1 |
| 2/04/2022 | Nuvectis Pharma | <u>Phase I</u> | <u>47.6</u> | <u>5.7</u> | <u>0.0</u> | 41.9 |
| 1/13/2022 | Tharimmune | <u>Pre-clinical</u> | <u>29.9</u> | <u>0.0</u> | <u>2.2</u> | 32.1 |
| 10/22/2021 | Xilio Therapeutics | <u>Phase I</u> | <u>309.0</u> | <u>99.8</u> | <u>9.6</u> | 218.8 |
| 10/07/2021 | Pyxis Oncology | <u>Pre-clinical</u> | <u>355.7</u> | <u>133.5</u> | <u>0.0</u> | 222.2 |
| 9/15/2021 | Tyra Biosciences | <u>Pre-clinical</u> | <u>481.8</u> | <u>135.2</u> | <u>0.0</u> | 346.6 |
| 7/29/2021 | Omega Therapeutics | <u>Pre-clinical</u> | <u>668.5</u> | <u>122.4</u> | <u>11.8</u> | 557.9 |
| 6/17/2021 | Lyell Immunopharma | <u>Pre-clinical</u> | <u>3,703.1</u> | <u>604.9</u> | <u>0.0</u> | 3,098.2 |
| 6/11/2021 | Janux Therapeutics | <u>Pre-clinical</u> | <u>484.5</u> | <u>70.7</u> | <u>0.0</u> | 413.8 |
| 5/04/2021 | Werewolf Therapeutics | <u>Pre-clinical</u> | <u>320.6</u> | <u>84.6</u> | <u>0.0</u> | 236.0 |
| 2/04/2021 | Bolt Biotherapeutics | <u>Phase I</u> | <u>460.4</u> | <u>22.8</u> | <u>0.0</u> | 437.6 |
| 9/25/2020 | Prelude Therapeutics | <u>Phase I</u> | <u>648.5</u> | <u>29.7</u> | <u>0.0</u> | 618.8 |
| 8/14/2020 | CureVac N.V. | <u>Phase I</u> | <u>2,602.2</u> | <u>49.3</u> | <u>67.1</u> | 2,619.9 |
| 7/16/2020 | Relay Therapeutics | <u>Phase I</u> | <u>1,337.5</u> | <u>312.2</u> | <u>0.0</u> | 1,025.3 |
| 4/24/2020 | ORIC Pharmaceuticals | <u>Phase I</u> | <u>340.7</u> | <u>79.4</u> | <u>0.0</u> | 261.3 |
| 1/30/2020 | Black Diamond | <u>Pre-clinical</u> | <u>451.0</u> | <u>154.7</u> | <u>0.0</u> | 296.3 |

| | | | | | | |
|-----------|----------------------|-----------------------|---------------------|--------------------|--------------------|-------|
| | Therapeutics | | | | | |
| 5/22/2019 | Bicycle Therapeutics | <u>Phase I</u> | <u>187.1</u> | <u>59.4</u> | <u>0.0</u> | 127.7 |
| 9/27/2018 | Gritstone Bio | <u>Phase I</u> | <u>332.4</u> | <u>64.5</u> | <u>10.5</u> | 278.4 |

The disclosure under the heading “*Selected Publicly Traded Companies*” is hereby amended and supplemented by replacing the table on page 138 of the Form S-4 in its entirety with the following:

| Company | Ticker | Stage | Market Cap (\$m) | Debt (\$m) | Cash (\$m) | Enterprise Value (\$m) |
|------------------------|-------------|----------------|------------------|-------------|--------------|------------------------|
| Janux Therapeutics | <u>JANX</u> | <u>Phase I</u> | <u>2,786.0</u> | <u>0.0</u> | <u>646.3</u> | 2,139.7 |
| Enliven Therapeutics | <u>ELVN</u> | <u>Phase I</u> | <u>1,360.9</u> | <u>0.0</u> | <u>312.4</u> | 1,048.5 |
| Tyra Biosciences | <u>TYRA</u> | <u>Phase I</u> | <u>1,158.0</u> | <u>0.0</u> | <u>373.8</u> | 784.2 |
| Bicara Therapeutics | <u>BCAX</u> | <u>Phase I</u> | <u>1,223.7</u> | <u>0.0</u> | <u>565.9</u> | 657.8 |
| Immatics | <u>IMTX</u> | <u>Phase I</u> | <u>1,105.2</u> | <u>0.0</u> | <u>718.5</u> | 386.7 |
| ORIC Pharmaceuticals | <u>ORIC</u> | <u>Phase I</u> | <u>574.9</u> | <u>0.0</u> | <u>308.5</u> | 266.4 |
| Instil Bio | <u>TIL</u> | <u>Phase I</u> | <u>202.0</u> | <u>81.9</u> | <u>148.8</u> | 135.2 |
| Mersana Therapeutics | <u>MRSN</u> | <u>Phase I</u> | <u>233.1</u> | <u>25.4</u> | <u>162.7</u> | 95.7 |
| Context Therapeutics | <u>CNTX</u> | <u>Phase I</u> | <u>175.5</u> | <u>0.0</u> | <u>101.5</u> | 74.0 |
| Corbus Pharmaceuticals | <u>CRBP</u> | <u>Phase I</u> | <u>196.4</u> | <u>10.8</u> | <u>147.0</u> | 60.2 |
| TScan Therapeutics | <u>TCRX</u> | <u>Phase I</u> | <u>257.5</u> | <u>30.4</u> | <u>297.7</u> | (9.8) |
| Fate Therapeutics | <u>FATE</u> | <u>Phase I</u> | <u>301.8</u> | <u>0.0</u> | <u>352.0</u> | (50.2) |
| CytomX Therapeutics | <u>CTMX</u> | <u>Phase I</u> | <u>80.5</u> | <u>0.0</u> | <u>137.2</u> | (56.7) |

The disclosure under the heading “*Selected Publicly Traded Companies*” is hereby amended and supplemented by replacing the first table on page 139 of the Form S-4 in its entirety with the following:

| Company | Ticker | Stage | Market Cap (\$m) | Debt (\$m) | Cash (\$m) | Enterprise Value (\$m) |
|-----------------------|-------------|---------------------|------------------|-------------|--------------|------------------------|
| Apogee Therapeutics | <u>APGE</u> | <u>Phase II</u> | <u>3,113.2</u> | <u>0.0</u> | <u>789.6</u> | 2,323.6 |
| Spyre Therapeutics | <u>SYRE</u> | <u>Phase I</u> | <u>1,772.5</u> | <u>0.0</u> | <u>426.0</u> | 1,346.5 |
| Viridian Therapeutics | <u>VRDN</u> | <u>Phase III</u> | <u>1,759.8</u> | <u>20.5</u> | <u>796.4</u> | 983.9 |
| Cogent Biosciences | <u>COGT</u> | <u>Phase III</u> | <u>1,310.1</u> | <u>0.0</u> | <u>389.9</u> | 920.2 |
| Oruka Therapeutics | <u>ORKA</u> | <u>Pre-clinical</u> | <u>979.6</u> | <u>0.0</u> | <u>475.0</u> | 504.6 |
| Astria Therapeutics | <u>ATXS</u> | <u>Phase Ib/II</u> | <u>647.2</u> | <u>0.0</u> | <u>354.7</u> | 292.5 |

The disclosure under the heading “*Selected Precedent M&A Transactions*” is hereby amended and supplemented by replacing the second table on page 139 of the Form S-4 in its entirety with the following:

| Closed Date | Target | Acquirer | Stage | Implied Enterprise Value (\$m*) |
|-------------|--------------------|----------------------|---------------------|---------------------------------|
| 7/29/2024 | Nerio Therapeutics | Boehringer Ingelheim | <u>Pre-clinical</u> | 1,300.0 |
| 5/02/2024 | Mariana Oncology | Novartis | <u>Pre-clinical</u> | 1,000.0 |
| 4/03/2024 | Kinnate Biopharma | XOMA Royalty Corp. | <u>Phase I</u> | 115.3 |
| 11/22/2023 | T3 Pharma | Boehringer Ingelheim | <u>Phase I</u> | 509.0 |
| 1/16/2023 | Neogene | AstraZeneca | <u>Pre-clinical</u> | 200.0 |
| 9/07/2022 | Good Therapeutics | Roche | <u>Pre-clinical</u> | 250.0 |
| 12/10/2021 | NBE Therapeutics | Boehringer Ingelheim | <u>Phase I</u> | 1,180.0 |
| 1/23/2020 | Synthorx | Sanofi | <u>Pre-clinical</u> | 2,350.0 |
| 5/31/2018 | AurKa Pharma | Eli Lilly | <u>Phase I</u> | 110.0 |

***Enterprise value excludes contingent milestone payments when disclosure allowed.**

The disclosure under the heading “*Selected Precedent Reverse Merger Transactions*” is hereby amended and supplemented by replacing the table on page 140 and carrying over through page 142 of the Form S-4 in its entirety with the following:

| Closed Date | Surviving Company (Private) | Public Vehicle (Ticker) | Public Co. Cash at Close (\$ mm) | Value Delivered Net of Cash (\$ mm) | Public Co. % Ownership of NewCo | Equity Value at Merger (\$ mm) | Enterprise Value at Merger (\$ mm) | Concurrent (\$ mm) |
|----------------|---------------------------------|--------------------------------------------------|----------------------------------|-------------------------------------|---------------------------------|--------------------------------|------------------------------------|--------------------|
| 10 / 17 / 2024 | TuHURA Biosciences | <u>Kintara Therapeutics (KTRA)</u> | <u>1</u> | 10 | <u>6 %</u> | <u>191</u> | <u>160</u> | <u>31</u> |
| 10 / 09 / 2024 | Wex Pharmaceuticals ("Dogwood") | <u>Virios Therapeutics (VIRI)</u> | <u>0</u> | 6 | <u>6 %</u> | <u>99</u> | <u>99</u> | <u>20</u> |
| 08 / 29 / 2024 | Oruka Therapeutics | <u>ARCA Biopharma (ABIO)</u> | <u>5</u> | 6 | <u>2 %</u> | <u>450</u> | <u>175</u> | <u>275</u> |
| 08 / 12 / 2024 | Firefly Neurosciences | <u>WaveDancer (WAVD)</u> | <u>1</u> | 14 | <u>8 %</u> | <u>110</u> | <u>110</u> | <u>4</u> |
| 06 / 20 / 2024 | Tetonic Therapeutic | <u>AVROBIO (AVRO)</u> | <u>65</u> | 13 | <u>25 %</u> | <u>140</u> | <u>140</u> | <u>131</u> |
| 04 / 01 / 2024 | Tawsfynydd Therapeutics | <u>Onconova Therapeutics (ONTX)</u> | <u>7</u> | 11 | <u>14 %</u> | <u>100</u> | <u>104</u> | <u>14</u> |
| 03 / 26 / 2024 | Serina Therapeutics | <u>AgeX Therapeutics (AGE)</u> | <u>24</u> | 6 | <u>25 %</u> | <u>90</u> | <u>83</u> | <u>15</u> |
| 03 / 25 / 2024 | Q32 Bio | <u>Homology Medicines (FIXX)</u> | <u>60</u> | 20 | <u>26 %</u> | <u>195</u> | <u>195</u> | <u>42</u> |
| 03 / 21 / 2024 | LENZ Therapeutics | <u>Graphite Bio (GRPH)</u> | <u>115</u> | 12 | <u>31 %</u> | <u>232</u> | <u>232</u> | <u>54</u> |
| 03 / 14 / 2024 | Immunogenx (Entero Tx) | <u>First Wave BioPharma (FWBI)</u> | <u>4</u> | 15 | <u>18 %</u> | <u>85</u> | <u>95</u> | <u>—</u> |
| 03 / 06 / 2024 | Adaptive Phage Therapeutics | <u>BiomX (PHGE)</u> | <u>N/A</u> | N/A | <u>55 %</u> | <u>N/A</u> | <u>N/A</u> | <u>50</u> |
| 12 / 27 / 2023 | Cyclo Therapeutics | <u>Applied Molecular Transport (AMTI)</u> | <u>12</u> | 1 | <u>25 %</u> | <u>41</u> | <u>28</u> | <u>—</u> |

| Closed Date | Surviving Company (Private) | Public Vehicle (Ticker) | Public Co. Cash at Close (\$ mm) | Value Delivered Net of Cash (\$ mm) | Public Co. % Ownership of NewCo | Equity Value at Merger (\$ mm) | Enterprise Value at Merger (\$ mm) | Concurrent (\$ mm) |
|----------------|-----------------------------|-----------------------------------------|----------------------------------|-------------------------------------|---------------------------------|--------------------------------|------------------------------------|--------------------|
| 12 / 18 / 2023 | Neurogene | <u>Neoleukin Therapeutics (NLTX)</u> | <u>42</u> | 14 | <u>16 %</u> | <u>295</u> | <u>200</u> | <u>95</u> |
| 12 / 15 / 2023 | ProteoMedix (Onconetix) | <u>Blue Water Biotech (BWV)</u> | <u>N/A</u> | N/A | <u>20 %</u> | <u>75</u> | <u>52</u> | <u>=</u> |
| 11 / 13 / 2023 | Cartesian Therapeutics | <u>Selecta Biosciences (RNAC)</u> | <u>50</u> | 13 | <u>27 %</u> | <u>170</u> | <u>170</u> | <u>60</u> |
| 11 / 03 / 2023 | Korro Bio | <u>Frequency Therapeutics (FREQ)</u> | <u>25</u> | 15 | <u>8 %</u> | <u>326</u> | <u>298</u> | <u>117</u> |
| 10 / 31 / 2023 | Lung Therapeutics | <u>Aileron Therapeutics (ALRN)</u> | <u>8</u> | 10 | <u>17 %</u> | <u>90</u> | <u>90</u> | <u>18</u> |
| 10 / 16 / 2023 | Notable Labs | <u>Vascular Biogenics (VBLT)</u> | <u>15</u> | 20 | <u>25 %</u> | <u>110</u> | <u>95</u> | <u>10</u> |
| 09 / 11 / 2023 | Dianthus Therapeutics | <u>Magenta Therapeutics (MGTA)</u> | <u>65</u> | 20 | <u>22 %</u> | <u>225</u> | <u>225</u> | <u>70</u> |
| 08 / 16 / 2023 | EIP Pharma (CervoMed) | <u>Diffusion Pharmaceuticals (DFFN)</u> | <u>12</u> | 10 | <u>22 %</u> | <u>79</u> | <u>79</u> | <u>=</u> |
| 06 / 29 / 2023 | TeraImmune | <u>Baudax Bio (BRRX)</u> | <u>N/A</u> | 3 | <u>18 %</u> | <u>10</u> | <u>10</u> | <u>=</u> |
| 06 / 22 / 2023 | Spyre Therapeutics | <u>Aeglea BioTherapeutics (AGLE)</u> | <u>10</u> | 25 | <u>5 %</u> | <u>110</u> | <u>110</u> | <u>210</u> |
| 06 / 01 / 2023 | Elicio Therapeutics | <u>Angion Biomedica (ANGN)</u> | <u>27</u> | 7 | <u>35 %</u> | <u>95</u> | <u>95</u> | <u>=</u> |
| 04 / 22 / 2023 | GRI Bio | <u>Vallon Pharmaceuticals (VLON)</u> | <u>=</u> | 29 | <u>17 %</u> | <u>65</u> | <u>49</u> | <u>15</u> |

| Closed Date | Surviving Company (Private) | Public Vehicle (Ticker) | Public Co. Cash at Close (\$ mm) | Value Delivered Net of Cash (\$ mm) | Public Co. % Ownership of NewCo | Equity Value at Merger (\$ mm) | Enterprise Value at Merger (\$ mm) | Concurrent (\$ mm) |
|----------------|-----------------------------|---------------------------------------|----------------------------------|-------------------------------------|---------------------------------|--------------------------------|------------------------------------|--------------------|
| 03 / 20 / 2023 | CalciMedica | <u>Graybug Vision (GRAY)</u> | <u>25</u> | 15 | <u>28 %</u> | <u>100</u> | <u>100</u> | <u>10</u> |
| 03 / 07 / 2023 | Carisma Therapeutics | <u>Sesen Bio (SESN)</u> | <u>110</u> | 15 | <u>25 %</u> | <u>196</u> | <u>196</u> | <u>30</u> |
| 02 / 23 / 2023 | Enliven Therapeutics | <u>Imara (IMRA)</u> | <u>82</u> | 10 | <u>16 %</u> | <u>489</u> | <u>325</u> | <u>165</u> |
| 01 / 09 / 2023 | Catheter Precision | <u>Ra Medical Systems (RMED)</u> | <u>6</u> | 4 | <u>12 %</u> | <u>62</u> | <u>63</u> | <u>9</u> |
| 12 / 29 / 2022 | Disc Medicine | <u>Gemini Therapeutics (GMTX)</u> | <u>90</u> | 10 | <u>26 %</u> | <u>314</u> | <u>260</u> | <u>54</u> |
| 12 / 27 / 2022 | GNI Group (Gyre Tx) | <u>Catalyst Biosciences (CBIO)</u> | <u>1</u> | 9 | <u>3 %</u> | <u>334</u> | <u>333</u> | <u>=</u> |
| 12 / 19 / 2022 | Kineta, Inc. | <u>Yumanity Therapeutics (YMTX)</u> | <u>8</u> | 26 | <u>15 %</u> | <u>194</u> | <u>194</u> | <u>30</u> |
| 11 / 08 / 2022 | ARS Pharmaceuticals | <u>Silverback Therapeutics (SBTX)</u> | <u>265</u> | 5 | <u>38 %</u> | <u>441</u> | <u>426</u> | <u>=</u> |
| 09 / 28 / 2022 | Aceragen, Inc. | <u>Idera Pharmaceuticals (IDRA)</u> | <u>21</u> | 7 | <u>33 %</u> | <u>57</u> | <u>42</u> | <u>=</u> |
| 09 / 15 / 2022 | Lisata Therapeutics (Cend) | <u>Caladrius Biosciences (CLBS)</u> | <u>65</u> | 25 | <u>50 %</u> | <u>90</u> | <u>84</u> | <u>=</u> |
| 08 / 30 / 2022 | Vivani Medical | <u>Second Sight Medical (EYES)</u> | <u>55</u> | N/A | <u>23 %</u> | <u>141</u> | <u>131</u> | <u>=</u> |
| 07 / 05 / 2022 | Syros Pharmaceuticals | <u>Tyme Technologies (TYME)</u> | <u>62</u> | 8 | <u>27 %</u> | <u>189</u> | <u>141</u> | <u>130</u> |
| 05 / 16 / 2022 | Aprea Therapeutics | <u>Atrin Pharmaceuticals (APRE)</u> | <u>35</u> | 15 | <u>41 %</u> | <u>75</u> | <u>75</u> | <u>=</u> |
| 10 / 24 / 2021 | Quoin Pharmaceuticals | <u>Cellect Biotechnology (APOF)</u> | <u>5</u> | 13 | <u>25 %</u> | <u>56</u> | <u>51</u> | <u>22</u> |

| Closed Date | Surviving Company (Private) | Public Vehicle (Ticker) | Public Co. Cash at Close (\$ mm) | Value Delivered Net of Cash (\$ mm) | Public Co. % Ownership of NewCo | Equity Value at Merger (\$ mm) | Enterprise Value at Merger (\$ mm) | Concurrent (\$ mm) |
|----------------|--------------------------------|------------------------------------------------|----------------------------------|-------------------------------------|---------------------------------|--------------------------------|------------------------------------|--------------------|
| 08 / 26 / 2021 | Aadi Bioscience | <u>Aerpio Pharmaceuticals (ARPO)</u> | <u>28</u> | 15 | <u>52 %</u> | <u>82</u> | <u>79</u> | <u>155</u> |
| 08 / 03 / 2021 | Decoy Biosystems | <u>Indaptus Therapeutics (INDP)</u> | <u>2</u> | 10 | <u>34 %</u> | <u>65</u> | <u>35</u> | <u>30</u> |
| 07 / 27 / 2021 | Cytocom (Statera) | <u>Cleveland BioLabs (CBLI)</u> | <u>3</u> | N/A | <u>39 %</u> | <u>61</u> | <u>61</u> | <u>=</u> |
| 06 / 28 / 2021 | Tempest Therapeutics | <u>Millendo Therapeutics (MLND)</u> | <u>17</u> | 19 | <u>23 %</u> | <u>158</u> | <u>128</u> | <u>30</u> |
| 06 / 15 / 2021 | ReShape Lifesciences | <u>Obalon Therapeutics (OBLN)</u> | <u>4</u> | 15 | <u>49 %</u> | <u>19</u> | <u>28</u> | <u>=</u> |
| 04 / 27 / 2021 | Leading BioSciences (Palisade) | <u>Seneca Biopharma (SNCA)</u> | <u>5</u> | 30 | <u>35 %</u> | <u>98</u> | <u>78</u> | <u>20</u> |
| 04 / 16 / 2021 | MyMD Pharmaceuticals | <u>Akers Biosciences (AKER)</u> | <u>23</u> | 5 | <u>20 %</u> | <u>269</u> | <u>251</u> | <u>18</u> |
| 03 / 31 / 2021 | StemoniX (Vyant Bio) | <u>Cancer Genetics (CGIX)</u> | <u>2</u> | 15 | <u>22 %</u> | <u>60</u> | <u>60</u> | <u>=</u> |
| 03 / 16 / 2021 | ChemomAb Ltd. | <u>Anchiano Therapeutics (ANCN)</u> | <u>0</u> | 15 | <u>10 %</u> | <u>135</u> | <u>90</u> | <u>46</u> |
| 02 / 24 / 2021 | Viracta Therapeutics | <u>Sunesis Pharmaceuticals (SNSS)</u> | <u>14</u> | 16 | <u>14 %</u> | <u>185</u> | <u>120</u> | <u>65</u> |
| 01 / 28 / 2021 | Quellis Biosciences (Astria) | <u>Catabasis Pharmaceuticals (CATB)</u> | <u>37</u> | 25 | <u>25 %</u> | <u>185</u> | <u>177</u> | <u>110</u> |
| 12 / 22 / 2020 | Yumanity Therapeutics | <u>Proteostasis Therapeutics (PTI)</u> | <u>29</u> | 34 | <u>29 %</u> | <u>154</u> | <u>120</u> | <u>34</u> |
| 12 / 01 / 2020 | Petros Pharmaceuticals | <u>Neurotrope (NTRP)</u> | <u>N/A</u> | 4 | <u>=</u> | <u>N/A</u> | <u>N/A</u> | <u>=</u> |
| 11 / 23 / 2020 | F-star Therapeutics | <u>Spring Bank Pharmaceuticals</u> | <u>11</u> | 23 | <u>46 %</u> | <u>40</u> | <u>25</u> | <u>15</u> |
| 11 / 05 / 2020 | Ocuphire Pharma | <u>Rexahn Pharmaceuticals (REXN)</u> | <u>2</u> | 16 | <u>13 %</u> | <u>138</u> | <u>117</u> | <u>21</u> |

| Closed Date | Surviving Company (Private) | Public Vehicle (Ticker) | Public Co. Cash at Close (\$ mm) | Value Delivered Net of Cash (\$ mm) | Public Co. % Ownership of NewCo | Equity Value at Merger (\$ mm) | Enterprise Value at Merger (\$ mm) | Concurrent (\$ mm) |
|----------------|--------------------------------|---------------------------------------|----------------------------------|-------------------------------------|---------------------------------|--------------------------------|------------------------------------|--------------------|
| 10 / 27 / 2020 | Viridian Therapeutics | <u>Miragen Therapeutics (MGEN)</u> | <u>12</u> | 15 | <u>12 %</u> | <u>191</u> | <u>71</u> | <u>91</u> |
| 09 / 15 / 2020 | Adicet Bio | <u>resTORbio (TORC)</u> | <u>65</u> | 8 | <u>25 %</u> | <u>220</u> | <u>220</u> | <u>=</u> |
| 09 / 14 / 2020 | Anelixis Therapeutics (Eledon) | <u>Novus Therapeutics (NVUS)</u> | <u>5</u> | 5 | <u>5 %</u> | <u>183</u> | <u>75</u> | <u>108</u> |
| 07 / 06 / 2020 | Kiq Bio (Cogent) | <u>Unum Therapeutics (UMRX)</u> | <u>12</u> | 17 | <u>16 %</u> | <u>149</u> | <u>45</u> | <u>104</u> |
| 06 / 15 / 2020 | Forte Biosciences | <u>Tocagen (TOCA)</u> | <u>1</u> | 8 | <u>14 %</u> | <u>49</u> | <u>30</u> | <u>19</u> |
| 05 / 28 / 2020 | Larimar Therapeutics | <u>Zafgen (ZFGN)</u> | <u>40</u> | 5 | <u>23 %</u> | <u>148</u> | <u>68</u> | <u>80</u> |
| 05 / 26 / 2020 | Histogen, Inc. | <u>Conatus Pharmaceuticals (CNAT)</u> | <u>13</u> | 23 | <u>26 %</u> | <u>100</u> | <u>100</u> | <u>=</u> |
| 05 / 22 / 2020 | Qualigen, Inc. | <u>Ritter Pharmaceuticals (RTTR)</u> | <u>N/A</u> | N/A | <u>8 %</u> | <u>N/A</u> | <u>N/A</u> | <u>4</u> |
| 05 / 18 / 2020 | Timber Pharmaceuticals | <u>BioPharmX Corporation (BPMX)</u> | <u>2</u> | 16 | <u>12 %</u> | <u>106</u> | <u>86</u> | <u>20</u> |
| 04 / 01 / 2020 | Curetis NV | <u>OpGen (OPGN)</u> | <u>7</u> | 7 | <u>28 %</u> | <u>24</u> | <u>24</u> | <u>9</u> |
| 01 / 09 / 2020 | Protara Therapeutics | <u>Proteon Therapeutics (PRTO)</u> | <u>3</u> | 5 | <u>10 %</u> | <u>63</u> | <u>20</u> | <u>43</u> |
| 12 / 30 / 2019 | NeuroBo Pharmaceuticals | <u>Gemphire Therapeutics (GEMP)</u> | <u>8</u> | 4 | <u>4 %</u> | <u>118</u> | <u>94</u> | <u>24</u> |
| 11 / 07 / 2019 | Venus Concept | <u>Restoration Robotics (HAIR)</u> | <u>10</u> | 20 | <u>15 %</u> | <u>223</u> | <u>282</u> | <u>21</u> |

| Closed Date | Surviving Company (Private) | Public Vehicle (Ticker) | Public Co. Cash at Close (\$ mm) | Value Delivered Net of Cash (\$ mm) | Public Co. % Ownership of NewCo | Equity Value at Merger (\$ mm) | Enterprise Value at Merger (\$ mm) | Concurrent (\$ mm) |
|----------------|-----------------------------|---------------------------------------|----------------------------------|-------------------------------------|---------------------------------|--------------------------------|------------------------------------|--------------------|
| 09 / 27 / 2019 | Ocugen, Inc. | <u>Histogenics Corporation (HSGX)</u> | N/A | N/A | 17 % | N/A | N/A | 25 |
| 08 / 31 / 2019 | Brickell Biotech | <u>Vical Incorporated (VICL)</u> | 35 | 4 | 44 % | 50 | 50 | 25 |
| 07 / 31 / 2019 | ESSA Pharma | <u>Realm Therapeutics (RLM)</u> | 21 | 1 | 46 % | 45 | 45 | 36 |
| 07 / 22 / 2019 | Salarius Pharmaceuticals | <u>Flex Pharma (FLKS)</u> | 7 | 4 | 20 % | 36 | 30 | 6 |
| 07 / 15 / 2019 | NeuBase Therapeutics | <u>Ohr Pharmaceutical (OHRP)</u> | 1 | 7 | 15 % | 41 | 32 | 9 |
| 06 / 10 / 2019 | Oncternal Therapeutics | <u>GTx (GTXI)</u> | 15 | 9 | 23 % | 81 | 77 | = |
| 06 / 09 / 2019 | Edesa Biotech | <u>Stellar Biotechnologies (SBOT)</u> | 4 | 2 | 12 % | 42 | 37 | = |
| 05 / 09 / 2019 | Armata Pharmaceuticals | <u>Ampliphi Biosciences (APHB)</u> | 2 | 10 | 24 % | 28 | 22 | 10 |
| 05 / 06 / 2019 | Adynxx, Inc. | <u>Alliqua BioMedical (ALQA)</u> | 2 | 3 | 14 % | 29 | 21 | = |
| 04 / 23 / 2019 | Mereo BioPharma | <u>Oncomed Pharmaceuticals (OMED)</u> | 37 | 20 | 26 % | 222 | 213 | = |
| 04 / 12 / 2019 | Immunic AG | <u>Vital Therapies (VTL)</u> | 7 | 10 | 12 % | 85 | 79 | 30 |
| 03 / 26 / 2019 | Enlivex Therapeutics | <u>Bioblast Pharma (ORPN)</u> | 0 | 5 | 4 % | 108 | 100 | 8 |
| 03 / 18 / 2019 | PDS Biotechnology | <u>Edge Therapeutics (EDGE)</u> | 25 | 5 | 30 % | 70 | 70 | = |
| 03 / 13 / 2019 | X4 Pharmaceuticals | <u>Arsanis (ASNS)</u> | 21 | 29 | 30 % | 115 | 115 | = |
| 01 / 24 / 2019 | Seelos Therapeutics | <u>Apricus Biosciences (APRI)</u> | 3 | 8 | 14 % | 65 | 65 | 18 |
| 12 / 07 / 2018 | Millendo Therapeutics | <u>OvaScience (OVAS)</u> | 36 | 5 | 17 % | 155 | 155 | 50 |
| 10 / 12 / 2018 | Aravive Biologics | <u>Versartis (VSAR)</u> | 57 | 0 | 50 % | 54 | 50 | = |
| 02 / 13 / 2018 | Vaxart, Inc. | <u>Aviragen Therapeutics (AVIR)</u> | 30 | 44 | 49 % | 77 | 77 | = |
| 01 / 30 / 2018 | Innovate Biopharmaceuticals | <u>Monster Digital (MSDI)</u> | 0 | 6 | 9 % | 60 | 60 | 21 |
| 01 / 17 / 2018 | Evofem Biosciences | <u>Neoethetics (NEOT)</u> | 0 | 29 | 13 % | 171 | 151 | 20 |
| 01 / 04 / 2018 | Rocket Pharmaceuticals | <u>Inotek Pharmaceuticals (ITEK)</u> | 42 | 5 | 19 % | 200 | N/A | = |

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act) concerning GlycoMimetics, Crescent, the proposed transactions and other matters. These forward-looking statements include express or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company's listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive officers and directors of the combined company; each company's and the combined company's expected cash position at the closing of the proposed Merger (including completion of Crescent's pre-closing financing) and cash runway of the combined company; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical results; the combined company having sufficient resources to advance its pipeline candidates; and other statements that are not historical fact. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting GlycoMimetics, Crescent or the proposed transaction will be those that have been anticipated.

The forward-looking statements contained in this communication are based on current expectations and beliefs concerning future developments and their potential effects and therefore subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger, including GlycoMimetics' failure to obtain stockholder approval for the Merger, risks associated with the potential failure to complete the financing transaction in a timely manner or at all, risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability of each of GlycoMimetics and Crescent to consummate the transactions contemplated by the Merger, risks associated with GlycoMimetics' continued listing on Nasdaq until closing of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger prior to the closing or consummation of the Merger, risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on the combined company's business relationships, operating results and business generally; risks associated with the combined company's ability to manage expenses and unanticipated spending and costs that could reduce the combined company's cash resources; risks related to the combined company's ability to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby; the ability of the combined company to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; the combined company's ability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials; the combined company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; the combined company's ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments and the combined company's ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those risks and uncertainties and other factors more fully described in filings with the SEC, including the Form S-4 and reports filed on Form 10-K, 10-Q and 8-K and in other filings made by GlycoMimetics with the SEC from time to time and available at www.sec.gov. These forward-looking statements are based on current expectations, and with regard to the proposed transaction, are based on GlycoMimetics' current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management's beliefs and certain assumptions made by GlycoMimetics, all of which are subject to change. Such forward-looking statements are made as of the date of this release, and the parties undertake no obligation to update such statements to reflect subsequent events or circumstances, except as otherwise required by securities and other applicable law.

No Offer or Solicitation

This Current Report on Form 8-K is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information About the Proposed Transaction

This Current Report on Form 8-K does not substitute for the Form S-4, proxy statement/prospectus or for any other document that GlycoMimetics has filed or may file with the SEC in connection with the proposed transaction. In connection with the proposed transaction between GlycoMimetics and Crescent, GlycoMimetics has filed relevant materials with the SEC, including the Form S-4 that contains a proxy statement/prospectus.

GLYCOMIMETICS URGES INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT GLYCOMIMETICS, CRESCENT, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders can obtain free copies of the Form S-4 and other documents filed by GlycoMimetics with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and stockholders should note that GlycoMimetics communicates with investors and the public using its website (www.glycomimetics.com) and the investor relations website (www.glycomimetics.com/investor-relations) where anyone is able to obtain free copies of the Form S-4 and other documents filed by GlycoMimetics with the SEC and stockholders are urged to read the Form S-4 and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation

GlycoMimetics, Crescent and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the proposed transaction. Information about GlycoMimetics' directors and executive officers including a description of their interests in GlycoMimetics is included in GlycoMimetics' Annual Report on Form 10-K, as filed with the SEC on February 13, 2025, and in subsequent reports filed with the SEC. Additional information regarding these persons and their interests in the proposed transaction are included in the Form S-4 relating to the proposed transaction filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GlycoMimetics, Inc.
(Registrant)

Date: May 30, 2025

By: /s/ Brian Hahn
Brian Hahn
Principal Financial Officer
